215 related articles for article (PubMed ID: 19402060)
1. Immunotherapy of metastatic renal cell carcinoma.
McDermott DF
Cancer; 2009 May; 115(10 Suppl):2298-305. PubMed ID: 19402060
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy of metastatic renal cell carcinoma.
McDermott DF; Atkins MB
Cancer J; 2008; 14(5):320-4. PubMed ID: 18836337
[TBL] [Abstract][Full Text] [Related]
3. The application of high-dose interleukin-2 for metastatic renal cell carcinoma.
McDermott DF
Med Oncol; 2009; 26 Suppl 1():13-7. PubMed ID: 19148594
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy for renal cell carcinoma.
Rosenblatt J; McDermott DF
Hematol Oncol Clin North Am; 2011 Aug; 25(4):793-812. PubMed ID: 21763968
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy for advanced renal cell cancer.
Coppin C; Porzsolt F; Awa A; Kumpf J; Coldman A; Wilt T
Cochrane Database Syst Rev; 2005 Jan; (1):CD001425. PubMed ID: 15674877
[TBL] [Abstract][Full Text] [Related]
6. Update on the application of interleukin-2 in the treatment of renal cell carcinoma.
McDermott DF
Clin Cancer Res; 2007 Jan; 13(2 Pt 2):716s-720s. PubMed ID: 17255299
[TBL] [Abstract][Full Text] [Related]
7. Prognostic factors of the clinical response to subcutaneous immunotherapy with interleukin-2 alone in patients with metastatic renal cell carcinoma.
Lissoni P; Barni S; Ardizzoia A; Crispino S; Paolorossi F; Andres M; Scardino E; Tancini G
Oncology; 1994; 51(1):59-62. PubMed ID: 8265104
[TBL] [Abstract][Full Text] [Related]
8. Ten-year survival results in metastatic renal cell cancer patients treated with monoimmunotherapy with subcutaneous low-dose interleukin-2.
Lissoni P; Bordin V; Vaghi M; Fumagalli L; Bordoni A; Mengo S; Bucovec R; Fumagalli E; Malugani F; Ardizzoia A; Giani L; Gardani GS; Tancini G
Anticancer Res; 2002; 22(2B):1061-4. PubMed ID: 12168901
[TBL] [Abstract][Full Text] [Related]
9. Long-term follow-up of patients with metastatic renal cell carcinoma treated with intravenous recombinant interleukin-2 in Europe.
Negrier S; Maral J; Drevon M; Vinke J; Escudier B; Philip T
Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S93-8. PubMed ID: 10685667
[TBL] [Abstract][Full Text] [Related]
10. Clinical outcome of combined immunotherapy with interferon-alpha and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma.
Miyake H; Kurahashi T; Takenaka A; Inoue TA; Fujisawa M
Urol Oncol; 2009; 27(6):598-603. PubMed ID: 18818106
[TBL] [Abstract][Full Text] [Related]
11. A Phase I/Ib study of folate immune (EC90 vaccine administered with GPI-0100 adjuvant followed by EC17) with interferon-α and interleukin-2 in patients with renal cell carcinoma.
Amato RJ; Shetty A; Lu Y; Ellis PR; Mohlere V; Carnahan N; Low PS
J Immunother; 2014 May; 37(4):237-44. PubMed ID: 24714357
[TBL] [Abstract][Full Text] [Related]
12. Interleukin-2-based therapy for metastatic renal cell cancer: the Cytokine Working Group experience, 1989-1997.
Dutcher JP; Atkins M; Fisher R; Weiss G; Margolin K; Aronson F; Sosman J; Lotze M; Gordon M; Logan T; Mier J
Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S73-8. PubMed ID: 9457399
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy for renal cell carcinoma.
Bleumer I; Oosterwijk E; De Mulder P; Mulders PF
Eur Urol; 2003 Jul; 44(1):65-75. PubMed ID: 12814677
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy for advanced renal cell cancer.
Coppin C; Porzsolt F; Kumpf J; Coldman A; Wilt T
Cochrane Database Syst Rev; 2000; (3):CD001425. PubMed ID: 10908496
[TBL] [Abstract][Full Text] [Related]
15. Treatment of metastatic renal cell carcinoma.
Reeves DJ; Liu CY
Cancer Chemother Pharmacol; 2009 Jun; 64(1):11-25. PubMed ID: 19343348
[TBL] [Abstract][Full Text] [Related]
16. Rational selection of a control arm for randomised trials in metastatic renal cell carcinoma.
Mickisch GH
Eur Urol; 2003 Jun; 43(6):670-9. PubMed ID: 12767369
[TBL] [Abstract][Full Text] [Related]
17. Sarcomatoid renal cell carcinoma: biologic behavior, prognosis, and response to combined surgical resection and immunotherapy.
Cangiano T; Liao J; Naitoh J; Dorey F; Figlin R; Belldegrun A
J Clin Oncol; 1999 Feb; 17(2):523-8. PubMed ID: 10080595
[TBL] [Abstract][Full Text] [Related]
18. Renal cell carcinoma: novel treatments for advanced disease.
Huland E; Heinzer H
Curr Opin Urol; 2003 Nov; 13(6):451-6. PubMed ID: 14560137
[TBL] [Abstract][Full Text] [Related]
19. Novel immunotherapeutic strategies in development for renal cell carcinoma.
Inman BA; Harrison MR; George DJ
Eur Urol; 2013 May; 63(5):881-9. PubMed ID: 23084331
[TBL] [Abstract][Full Text] [Related]
20. Cytoreductive surgery in the management of metastatic renal cell carcinoma: the UCLA experience.
Franklin JR; Figlin R; Rauch J; Gitlitz B; Belldegrun A
Semin Urol Oncol; 1996 Nov; 14(4):230-6. PubMed ID: 8946623
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
